Anavex Life Sciences Corp. (NASDAQ: AVXL) is 1.08% higher on its value in year-to-date trading and has touched a low of $7.13 and a high of $15.24 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AVXL stock was last observed hovering at around $9.53 in the last trading session, with the day’s loss setting it -0.17% off its average median price target of $44.50 for the next 12 months. It is also 83.86% off the consensus price target high of $58.00 offered by 4 analysts, but current levels are 66.57% higher than the price target low of $28.00 for the same period.
Currently trading at $9.36, the stock is -5.30% and -8.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.4 million and changing -1.78% at the moment leaves the stock -9.42% off its SMA200. AVXL registered -7.14% loss for a year compared to 6-month gain of -0.53%.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
The stock witnessed a -10.86% loss in the last 1 month and extending the period to 3 months gives it a 7.96%, and is -7.42% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.58% over the week and 4.84% over the month.
Distance from 52-week low is 31.28% and -38.58% from its 52-week high.
Anavex Life Sciences Corp. (AVXL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Anavex Life Sciences Corp. (AVXL) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Anavex Life Sciences Corp. is expected to release its quarterly report on 05/11/2023.The EPS is expected to shrink by -14.90% this year
Anavex Life Sciences Corp. (AVXL) Top Institutional Holders
The shares outstanding are 77.98M, and float is at 75.61M with Short Float at 21.58%.
Anavex Life Sciences Corp. (AVXL) Insider Activity
A total of 0 insider transactions have happened at Anavex Life Sciences Corp. (AVXL) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Skarpelos Athanasios, the company’s Director. SEC filings show that Skarpelos Athanasios sold 50,000 shares of the company’s common stock on May 25 at a price of $9.06 per share for a total of $0.45 million. Following the sale, the insider now owns 1.31 million shares.
Anavex Life Sciences Corp. (AVXL): Who are the competitors?
The company’s main competitors (and peers) include Ligand Pharmaceuticals Incorporated (LGND) that is trading 9.51% up over the past 12 months and BioCryst Pharmaceuticals Inc. (BCRX) that is -47.06% lower over the same period. Palatin Technologies Inc. (PTN) is -70.27% down on the 1-year trading charts.